Background: We evaluated the Roche Elecsys® NeuroToolKit (NTK) assay panel of 12 cerebrospinal fluid (CSF) biomarkers in patients from a total of six clinical trials of crenezumab and gantenerumab in sporadic Alzheimer’s disease (AD), with respect to the correlations between individual biomarkers, and their associations with patient characteristics and disease severity. Additionally, we assessed their ability to measure and predict disease progression.Method: CSF samples were collected at baseline and follow‐up (Phase II, 1.5 years; Phase III, 1 and 2 years) from a subset of patients enrolled in the Phase II ABBY (NCT01343966)/BLAZE (NCT01397578) studies of crenezumab in mild‐to‐moderate AD, the Phase III CREAD (NCT02670083)/CREAD 2 (NCT03114657) studies of crenezumab in prodromal‐to‐mild AD, the Phase III SCarlet RoAD (NCT01224106) study of gantenerumab in prodromal AD, and the Phase III Marguerite RoAD (NCT02051608) study of gantenerumab in mild AD. NTK assays included beta‐amyloid (1‐42), beta‐amyloid (1‐40), alpha‐synuclein, GFAP, IL‐6, neurogranin, neurofilament light chain (NfL), phospho‐Tau (181P), S100B, sTREM2, total Tau, and YKL‐40. Correlations between biomarkers, longitudinal changes in biomarkers, and correlation between baseline biomarker levels and cognitive progression were evaluated across all six studies.Result: All biomarkers except IL‐6 positively correlated with each other; the highest correlations were between total Tau, phospho‐Tau (181P), and neurogranin (Spearman’s rho >0.9). NfL, GFAP, YKL‐40, and sTREM2 biomarkers positively correlated with patient age. Analyses of ABBY, BLAZE, CREAD, and CREAD2 showed consistent findings across all studies. Levels of NfL, GFAP, and α‐synuclein biomarkers increased at the 1 year and 1.5‐year timepoints. NfL correlated with disease severity and progression in the prodromal‐to‐mild population. Additionally, results from NTK measurements in SCarlet RoAD and Marguerite RoAD CSF samples will also be presented.Conclusion: The NTK provided robust data and sufficient measuring range for the biomarkers tested. Further evaluation of these biomarkers is needed to understand their potential utility for clinical trials as pharmacodynamic biomarkers or for selecting patient populations. Elecsys is a trademark of Roche.